Under the title "Telemedical Care of Men with Androgenetic Alopecia Demonstrates Improved Access to Care and Patient Benefit", Spring is publishing the world's first scientific study on male pattern hair loss based on telemedical data in a research collaboration with the Medical Center Hamburg-Eppendorf. The study was published by the renowned journal “Journal of the European Academy of Dermatology and Venereology.”
Quote Johannes v. Büren
“Telemedicine platforms such as online prescription platforms represent a new type of medical care. Telemedicine has gained increasing acceptance in recent years, and its application in clinical practice is diverse. This is the world's first telemedicine study on male pattern hair loss. We believe it is important that more research be done in this area, as many tens of thousands of patients are being treated telemedically in this indication in the United States as well as in Europe.”
Quote Johannes v. Büren
“This study goes well beyond the epidemiological characterization of Spring's hair loss patient cohort. Based on the scientific analysis of medical data from around 3,000 patients, it shows how online platforms can lower access barriers and thus patients can start their treatment earlier. We consider this to be particularly relevant when it comes to hair loss, since starting treatment early increases the chances of successful therapy.”
Quote Johannes v. Büren
“We find it particularly interesting that patients who had already seen a doctor about their hair loss before starting their telemedicine treatment rated the quality of telemedicine care as equivalent.”
View entire study here
The results of our study demonstrate the potentials of telemedicine to gain a substantial number of untreated patients. By reducing treatment barriers, telemedicine platforms contribute to earlier diagnosis and improved access to care, both leading to higher treatment success. This study demonstrates the patient benefit of telemedical care for men with male pattern hair loss.
